Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 21

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Inhibition of tau neuronal internalization using anti-tau single domain antibodies

Danis, Clément, Dupré, Elian, Bouillet, Thomas, Denéchaud, Marine, Lefebvre, Camille, Nguyen, Marine, Mortelecque, Justine, Cantrelle, François-Xavier, Rain, Jean-Christophe, Hanoulle, Xavier, Colin, Morvane, Buée, Luc, Landrieu, Isabelle·2025·Nature Communications
DOI 10.1038/s41467-025-58383-4PMC PMC11965310
Open this paper in CoChat — free account

Abstract

In Alzheimer’s disease, tau pathology spreads across brain regions as the disease progresses. Intracellular tau can be released and taken up by nearby neurons. We evaluated single domain anti-tau antibodies, also called VHHs, as inhibitors of tau internalization. We identified three VHH inhibitors of tau uptake: A31, H3-2, and Z70 mut1. These VHHs compete with the membrane protein LRP1, a major receptor mediating neuronal uptake of tau. A31 and Z70 mut1 bind to microtubule binding domain repeats, which are involved in the interaction with LRP1. VHH H3-2 is the only VHH from our library that reduces the internalization of both monomeric tau and tau fibrils. VHH H3-2 binds a C-terminal tau epitope with high affinity. Its three-dimensional structure in complex with a tau peptide reveals a unique binding mode as a VHH-swapped dimer. These anti-tau VHHs are interesting tools to study tau prion-like propagation in tauopathies and potentially develop novel biotherapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-025-58383-4

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Overview of the tau epitopes recognized by the anti-tau VHHs used in this study and schematic representation of the tau neuronal uptake assays. a Schematic representation of the tau epitopes recognized by each anti-tau VHH. VHH B1-1 binds to the tau proline-rich domain (PRD). VHH C3-2 binds to the amino-acid sequence located between the PRD and the R1 repeat of the tau microtubule-binding domain (MTBD). VHH A31 binds to the PHF6* region within the R2 repeat (Supplementary Fig. 1). VHH Z70mut1 binds to the PHF6 region within the R3 repeat. VHH A5-2 binds to the R4 repeat. VHH F8-2, E2-2, and H3-2 bind to the C-terminal domain (C-ter) of tau (Supplementary Fig. 2). The epitopes were determined by 2D NMR interaction mapping experiments, as previously described28–30. b Schematic representation of the tau cellular uptake assay. Recombinant monomeric (tau_M) or fibrils of tau1N4R (tau_F) labeled with fluorescent dyes (Alexa546 and Atto565, respectively) and VHHs were co-incubated for 30 min at room temperature (RT). Tau-VHHs complexes were then incubated with primary neurons for 1 h at 37 °C. Finally, cells were washed and analyzed by confocal microscopy or lysed and transferred to a 96-well plate for fluorescence imaging. Created in BioRender. Tautou, M. (2025) https://BioRender.com/a27l880.
Fig. 1 Overview of the tau epitopes recognized by the anti-tau VHHs used in this study and schematic representation of the tau neuronal uptake assays. a Schematic representation of the tau epitopes recognized by each anti-tau VHH. VHH B1-1 binds to the tau proline-rich domain (PRD). VHH C3-2 binds to the amino-acid sequence located between the PRD and the R1 repeat of the tau microtubule-binding domain (MTBD). VHH A31 binds to the PHF6* region within the R2 repeat (Supplementary Fig. 1). VHH Z70mut1 binds to the PHF6 region within the R3 repeat. VHH A5-2 binds to the R4 repeat. VHH F8-2, E2-2, and H3-2 bind to the C-terminal domain (C-ter) of tau (Supplementary Fig. 2). The epitopes were determined by 2D NMR interaction mapping experiments, as previously described28–30. b Schematic representation of the tau cellular uptake assay. Recombinant monomeric (tau_M) or fibrils of tau1N4R (tau_F) labeled with fluorescent dyes (Alexa546 and Atto565, respectively) and VHHs were co-incubated for 30 min at room temperature (RT). Tau-VHHs complexes were then incubated with primary neurons for 1 h at 37 °C. Finally, cells were washed and analyzed by confocal microscopy or lysed and transferred to a 96-well plate for fluorescence imaging. Created in BioRender. Tautou, M. (2025) https://BioRender.com/a27l880.CC BY · PubMed Central
Fig. 2 Cellular internalization of monomeric tau is inhibited by anti-tau VHHs A31 and H3-2. a Inhibition of cellular uptake of monomeric tau1N4R by the anti-tau VHHs. Percentage of cellular tau uptake based on Alexa546 fluorescence signal coming from monomeric tau1N4R (50 nM) co-incubated with PBS (tau_M), RAP (100 nM), heparin (50 µg/mL), and the VHHs (100 nM). n = 4 independent experiments per condition. Data were normalized to the condition of tau1N4R pre-incubated with PBS as 100% of tau uptake. Box plots show the median (center line), 25th, 75th percentiles (box), and minimum and maximum values (whiskers), all data points are shown (single points). Data were analyzed using one-way nonparametric ANOVA (Kruskal-Wallis) with Dunn’s multiple comparison test ****p < 0.0001; ***p < 0.001). RAP, VHHs A31 (p = 0.0004), and H3-2 significantly reduced cellular tau uptake. b Confocal microscopy analysis of cellular tau uptake assay using recombinant tau1N4R labeled with Alexa546 dye and in the presence of PBS (tau_M), RAP, heparin, and VHHs A31, Z70mut1 or H3-2 (images are representative of a n = 2 independent experiments per condition). Tau was visualized in red, and nuclei in light blue. The scale bar is 10 µm.
Fig. 2 Cellular internalization of monomeric tau is inhibited by anti-tau VHHs A31 and H3-2. a Inhibition of cellular uptake of monomeric tau1N4R by the anti-tau VHHs. Percentage of cellular tau uptake based on Alexa546 fluorescence signal coming from monomeric tau1N4R (50 nM) co-incubated with PBS (tau_M), RAP (100 nM), heparin (50 µg/mL), and the VHHs (100 nM). n = 4 independent experiments per condition. Data were normalized to the condition of tau1N4R pre-incubated with PBS as 100% of tau uptake. Box plots show the median (center line), 25th, 75th percentiles (box), and minimum and maximum values (whiskers), all data points are shown (single points). Data were analyzed using one-way nonparametric ANOVA (Kruskal-Wallis) with Dunn’s multiple comparison test ****p < 0.0001; ***p < 0.001). RAP, VHHs A31 (p = 0.0004), and H3-2 significantly reduced cellular tau uptake. b Confocal microscopy analysis of cellular tau uptake assay using recombinant tau1N4R labeled with Alexa546 dye and in the presence of PBS (tau_M), RAP, heparin, and VHHs A31, Z70mut1 or H3-2 (images are representative of a n = 2 independent experiments per condition). Tau was visualized in red, and nuclei in light blue. The scale bar is 10 µm.CC BY · PubMed Central
Fig. 3 VHHs A31 and Z70mut1 block the cellular uptake of recombinant tau microtubule binding domain (tauMTBD). Cellular tauMTBD uptake assay performed using 0.5 µM of recombinant monomeric tauMTBD labeled with the Atto488 fluorophore. a Percentage of cellular tauMTBD uptake based on Atto488 fluorescence signal quantification in the conditions resulting from tauMTBD co-incubation with each of the VHHs anti-GFP, A31, Z70mut1, E2-2, and H3-2 at a concentration of 1 µM. n = 3 independent experiments per condition. Data were normalized to the percentage of uptake relative to the condition of tauMTBD pre-incubated with PBS, defined as 100% of tauMTBD uptake. Box plots show the median (center line), 25th, 75th percentiles (box), and minimum and maximum values (whiskers), all data points are shown (single points). Data were analyzed using one-way nonparametric ANOVA (Kruskal-Wallis) with Dunn’s multiple comparison test (****p < 0.0001; **p < 0.01). VHHs A31 and Z70mut1 (p = 0.0061) significantly reduced cellular tau uptake. b Confocal microscopy analysis of cellular tauMTBD uptake assay under the conditions described in (a) (images are representative of a n = 2 independent experiments per condition). TauMTBD is visualized in green, and nuclei in light blue. The scale bar is 10 µm.
Fig. 3 VHHs A31 and Z70mut1 block the cellular uptake of recombinant tau microtubule binding domain (tauMTBD). Cellular tauMTBD uptake assay performed using 0.5 µM of recombinant monomeric tauMTBD labeled with the Atto488 fluorophore. a Percentage of cellular tauMTBD uptake based on Atto488 fluorescence signal quantification in the conditions resulting from tauMTBD co-incubation with each of the VHHs anti-GFP, A31, Z70mut1, E2-2, and H3-2 at a concentration of 1 µM. n = 3 independent experiments per condition. Data were normalized to the percentage of uptake relative to the condition of tauMTBD pre-incubated with PBS, defined as 100% of tauMTBD uptake. Box plots show the median (center line), 25th, 75th percentiles (box), and minimum and maximum values (whiskers), all data points are shown (single points). Data were analyzed using one-way nonparametric ANOVA (Kruskal-Wallis) with Dunn’s multiple comparison test (****p < 0.0001; **p < 0.01). VHHs A31 and Z70mut1 (p = 0.0061) significantly reduced cellular tau uptake. b Confocal microscopy analysis of cellular tauMTBD uptake assay under the conditions described in (a) (images are representative of a n = 2 independent experiments per condition). TauMTBD is visualized in green, and nuclei in light blue. The scale bar is 10 µm.CC BY · PubMed Central
Fig. 4 Cellular internalization of tau fibrils is inhibited by the anti-tau VHH H3-2. a Inhibition of cellular uptake of fibrillar tau1N4R by the anti-tau VHHs. Percentage of cellular tau fibril uptake based on Atto565 fluorescence signal coming from tau1N4R fibrils co-incubated with PBS (tau_F), RAP (400 nM), heparin (50 µg/mL), and the VHHs (400 nM). n = 3 independent experiments per condition. Data were normalized to the condition of tau1N4R fibrils pre-incubated with PBS as 100% of tau uptake. Box plots show median (center line), 25th, 75th percentiles (box,) and minimum and maximum values (whiskers), all data points are shown (single points). Data were analyzed using one-way nonparametric ANOVA (Kruskal-Wallis) with Dunn’s multiple comparison test (****p < 0.0001; **p < 0.01). Heparin and VHH H3-2 (p = 0.0096) significantly reduced cellular tau fibril uptake. b Confocal microscopy analysis of fibrillar tau cellular assays using recombinant tau1N4R fibrils labeled with Atto565 dye and in the presence of PBS (tau_M), RAP, heparin, and VHHs A31, Z70mut1, or H3-2 (images are representative of a n = 2 independent experiments per condition). Tau was visualized in red, and nuclei in light blue. The scale bar is 10 µm.
Fig. 4 Cellular internalization of tau fibrils is inhibited by the anti-tau VHH H3-2. a Inhibition of cellular uptake of fibrillar tau1N4R by the anti-tau VHHs. Percentage of cellular tau fibril uptake based on Atto565 fluorescence signal coming from tau1N4R fibrils co-incubated with PBS (tau_F), RAP (400 nM), heparin (50 µg/mL), and the VHHs (400 nM). n = 3 independent experiments per condition. Data were normalized to the condition of tau1N4R fibrils pre-incubated with PBS as 100% of tau uptake. Box plots show median (center line), 25th, 75th percentiles (box,) and minimum and maximum values (whiskers), all data points are shown (single points). Data were analyzed using one-way nonparametric ANOVA (Kruskal-Wallis) with Dunn’s multiple comparison test (****p < 0.0001; **p < 0.01). Heparin and VHH H3-2 (p = 0.0096) significantly reduced cellular tau fibril uptake. b Confocal microscopy analysis of fibrillar tau cellular assays using recombinant tau1N4R fibrils labeled with Atto565 dye and in the presence of PBS (tau_M), RAP, heparin, and VHHs A31, Z70mut1, or H3-2 (images are representative of a n = 2 independent experiments per condition). Tau was visualized in red, and nuclei in light blue. The scale bar is 10 µm.CC BY · PubMed Central
Fig. 5 VHHs A31, Z70mut1 and H3-2 compete for the interaction between monomeric tau1N4R and LRP1 cluster III in vitro. Sensorgram (control subtracted data) of tau1N4R binding to immobilized LRP1 cluster III in the absence (black curve) or the presence of 30 (yellow curve), 100 (orange curve), and 300 nM (red curve) of (a) VHH E2-2, of (b) VHH A31, of (c) VHH Z70mut1 and of (d) VHH H3-2.
Fig. 5 VHHs A31, Z70mut1 and H3-2 compete for the interaction between monomeric tau1N4R and LRP1 cluster III in vitro. Sensorgram (control subtracted data) of tau1N4R binding to immobilized LRP1 cluster III in the absence (black curve) or the presence of 30 (yellow curve), 100 (orange curve), and 300 nM (red curve) of (a) VHH E2-2, of (b) VHH A31, of (c) VHH Z70mut1 and of (d) VHH H3-2.CC BY · PubMed Central
Fig. 6 VHH H3-2 binds with high affinity to its tau C-terminal epitope and dimerizes in vitro. a Sensorgrams (reference subtracted data) of multi-cycle kinetics (MCK) analysis performed on immobilized biotinylated VHH E2-2 and H3-2, with injections of increasing concentrations of tau[369–381] C-terminal peptide (from 3 nM to 100 µM and from 3 nM to 32 µM, respectively; n = 3 independent experiments). Black lines correspond to the fitted curves, red lines correspond to the measurements. KDs were obtained using the kinetic model and are presented as mean values ± standard deviation (b). The maximum response (RU) observed for each peptide concentration was plotted and represented as a concentration-response curve (CRC). Black lines correspond to the fitted curves, red dots to the mean of the maximum response (in RU), from experiment (a) for each peptide concentration. Error bars represent standard deviation. The KD and stoichiometric ratio (SR) values extracted from these data are shown. KDs were obtained using the steady-state fitting model and are presented as mean values ± standard deviation. The SR have been calculated from the Rmax of the biological replicate represented here. c Ribbon representation of the crystal structure of the complex between VHH H3-2 and the tau[369–381] C-terminal peptide. The CDR1, CDR2, and CDR3 loops of VHH H3-2 are colored in pink, in dark blue, and in red, respectively. The framework regions of the VHHs are shown in green for one subunit and yellow for the other. The tau[369–381] peptides are shown in cyan and light blue.
Fig. 6 VHH H3-2 binds with high affinity to its tau C-terminal epitope and dimerizes in vitro. a Sensorgrams (reference subtracted data) of multi-cycle kinetics (MCK) analysis performed on immobilized biotinylated VHH E2-2 and H3-2, with injections of increasing concentrations of tau[369–381] C-terminal peptide (from 3 nM to 100 µM and from 3 nM to 32 µM, respectively; n = 3 independent experiments). Black lines correspond to the fitted curves, red lines correspond to the measurements. KDs were obtained using the kinetic model and are presented as mean values ± standard deviation (b). The maximum response (RU) observed for each peptide concentration was plotted and represented as a concentration-response curve (CRC). Black lines correspond to the fitted curves, red dots to the mean of the maximum response (in RU), from experiment (a) for each peptide concentration. Error bars represent standard deviation. The KD and stoichiometric ratio (SR) values extracted from these data are shown. KDs were obtained using the steady-state fitting model and are presented as mean values ± standard deviation. The SR have been calculated from the Rmax of the biological replicate represented here. c Ribbon representation of the crystal structure of the complex between VHH H3-2 and the tau[369–381] C-terminal peptide. The CDR1, CDR2, and CDR3 loops of VHH H3-2 are colored in pink, in dark blue, and in red, respectively. The framework regions of the VHHs are shown in green for one subunit and yellow for the other. The tau[369–381] peptides are shown in cyan and light blue.CC BY · PubMed Central
Fig. 7 VHH H3-2 spontaneously dimerizes in solution and its dimerization is stabilized by binding to tau[369–381] C-terminal peptide. a Size exclusion chromatography (SEC) analysis (A280 nm) performed on either VHH E2-2 (blue curve) and VHH H3-2 (red curve) alone, or in the presence of a 2-fold excess of the tau[369–381] C-terminal peptide (ratio 1: 2, green and yellow curves, respectively). Elution peaks corresponding to VHH monomer and dimer species are highlighted on the chromatogram (chromatogram is representative of a n = 2 independent experiments). Estimation of the VHH molecular weights was performed using a calibration curve obtained from SEC analysis of proteins of known size (Supplementary Fig. 15). b Schematic representation of the homogeneous time-resolved fluorescence (HTRF) assay performed with VHHs H3-2 and E2-2. Terbium (Tb) and D2 fluorophores correspond to the donor and acceptor, respectively. c Plotted HTRF ratio data corresponding to the concentration-response curve of the tau[369–381] C-terminal peptide in the presence of 6Histag-H3-2: donor and 6Histag-H3-2: acceptor (red dots, n = 3 independent experiments) or 6Histag-E2-2: donor and 6Histag-E2-2: acceptor (blue dots, n = 2 independent experiments). Data are presented as mean ± standard error of the mean for VHH H3-2 or mean only for VHH E2-2. An increase in the HTRF signal ratio is observed when the peptide concentration is increased in the presence of VHH H3-2 paired fluorophores. EC50 mean value was obtained using the non-linear fit ([ligand] vs. response, 3 parameters) model.
Fig. 7 VHH H3-2 spontaneously dimerizes in solution and its dimerization is stabilized by binding to tau[369–381] C-terminal peptide. a Size exclusion chromatography (SEC) analysis (A280 nm) performed on either VHH E2-2 (blue curve) and VHH H3-2 (red curve) alone, or in the presence of a 2-fold excess of the tau[369–381] C-terminal peptide (ratio 1: 2, green and yellow curves, respectively). Elution peaks corresponding to VHH monomer and dimer species are highlighted on the chromatogram (chromatogram is representative of a n = 2 independent experiments). Estimation of the VHH molecular weights was performed using a calibration curve obtained from SEC analysis of proteins of known size (Supplementary Fig. 15). b Schematic representation of the homogeneous time-resolved fluorescence (HTRF) assay performed with VHHs H3-2 and E2-2. Terbium (Tb) and D2 fluorophores correspond to the donor and acceptor, respectively. c Plotted HTRF ratio data corresponding to the concentration-response curve of the tau[369–381] C-terminal peptide in the presence of 6Histag-H3-2: donor and 6Histag-H3-2: acceptor (red dots, n = 3 independent experiments) or 6Histag-E2-2: donor and 6Histag-E2-2: acceptor (blue dots, n = 2 independent experiments). Data are presented as mean ± standard error of the mean for VHH H3-2 or mean only for VHH E2-2. An increase in the HTRF signal ratio is observed when the peptide concentration is increased in the presence of VHH H3-2 paired fluorophores. EC50 mean value was obtained using the non-linear fit ([ligand] vs. response, 3 parameters) model.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 58

  1. Glynn, C., Rodriguez, J. A. & Hyman, B. T. The structural line between prion and ‘prion-like’: Insights from prion protein and tau. Curr. Opin. Neurobiol. 86, 102857 (2024). · DOI
  2. Zampar, S., Di Gregorio, S. E., Grimmer, G., Watts, J. C. & Ingelsson, M. ‘Prion-like’ seeding and propagation of oligomeric protein assemblies in neurodegenerative disorders. Front. Neurosci. 18, 1436262 (2024). · DOI
  3. Vazquez-Sanchez, S. et al. Frontotemporal dementia-like disease progression elicited by seeded aggregation and spread of FUS. Mol. Neurodegener. 19, 46 (2024). · DOI
  4. Pongrácová, E., Buratti, E. & Romano, M. Prion-like Spreading of Disease in TDP-43 Proteinopathies. Brain Sci. 14, 1132 (2024). · DOI
  5. Neupane, K. et al. Direct observation of prion-like propagation of protein misfolding templated by pathogenic mutants. Nat. Chem. Biol. 20, 1220–1226 (2024). · DOI
  6. Tullo, S. et al. Neuroanatomical and cognitive biomarkers of alpha-synuclein propagation in a mouse model of synucleinopathy prior to onset of motor symptoms. J. Neurochem. 168, 1546–1564 (2024). · DOI
  7. Mudher, A. et al. What is the evidence that tau pathology spreads through prion-like propagation? Acta Neuropathol. Commun. 5, 99 (2017). · DOI · Paper page
  8. Colin, M. et al. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol 139, 3–25 (2020). · DOI · Paper page
  9. De La-Rocque, S., Moretto, E., Butnaru, I. & Schiavo, G. Knockin’ on heaven’s door: Molecular mechanisms of neuronal tau uptake. J. Neurochem. 156, 563–588 (2021). · DOI
  10. Rauch, J. N. et al. Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs). Sci. Rep. 8, 6382 (2018). · DOI · Paper page
  11. Stopschinski, B. E. et al. Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau versus α-synuclein and β-amyloid. J. Biol. Chem. 293, 10826–10840 (2018). · DOI · Paper page
  12. Marvian, A. T. et al. Distinct regulation of Tau Monomer and aggregate uptake and intracellular accumulation in human neurons. Mol. Neurodegener. 19, 100 (2024). · DOI
  13. Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446–448 (1993). · DOI · Paper page
  14. Monté, D. et al. Crystal structure of human Mediator subunit MED23. Nat. Commun. 9, 3389 (2018). · DOI
  15. Rasmussen, S. G. F. et al. Crystal structure of the β2Adrenergic receptor-Gs protein complex. Nature 477, 549–555 (2011). · DOI · Paper page
  16. Robertson, M. J. et al. Structure determination of inactive-state GPCRs with a universal nanobody. Nat. Struct. Mol. Biol. 29, 1188–1195 (2022). · DOI
  17. D’Huyvetter, M. et al. Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in Breast cancer patients. J. Nucl. Med. 62, 1097–1105 (2021). · DOI
  18. Duray, E. et al. A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. J. Hematol. Oncol. 14, 183 (2021). · DOI
  19. De Genst, E. J. et al. Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. J. Mol. Biol 402, 326–343 (2010). · DOI
  20. Guilliams, T. et al. Nanobodies raised against monomeric α-synuclein distinguish between fibrils at different maturation stages. J. Mol. Biol. 425, 2397–2411 (2013). · DOI
  21. Marino, M. et al. AAV‐mediated delivery of an anti‐BACE1 VHH alleviates pathology in an Alzheimer’s disease model. EMBO Mol. Med. 14, e09824 (2022). · DOI
  22. Li, T. et al. Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets. J. Control. Release 243, 1–10 (2016). · DOI
  23. Abskharon, R. et al. Structure-based design of nanobodies that inhibit seeding of Alzheimer’s patient-extracted tau fibrils. Proc. Natl. Acad. Sci. USA 120, e2300258120 (2023). · DOI
  24. Jiang, Y. et al. Single-domain antibody-based noninvasive in vivo imaging of α-synuclein or tau pathology. Sci. Adv. 9, eadf3775 (2023). · DOI
  25. Dupré, E. et al. Single domain antibody fFragments as new tools for the detection of neuronal tau protein in cells and in mice studies. ACS Chem. Neurosci. 10, 3997–4006 (2019). · DOI
  26. Danis, C. et al. Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment. Mol. Ther. 30, 1484–1499 (2022). · DOI · Paper page
  27. Mortelecque, J. et al. A selection and optimization strategy for single-domain antibodies targeting the PHF6 linear peptide within the tau intrinsically disordered protein. J. Biol. Chem. 300, 107163 (2024). · DOI · Paper page
  28. Benn, J. et al. Aggregate-selective removal of pathological tau by clustering-activated degraders. Science 385, 1009–1016 (2024). · DOI
  29. De Genst, E. et al. Strong in vivo maturation compensates for structurally restricted H3 loops in antibody repertoires. J. Biol. Chem. 280, 14114–14121 (2005). · DOI
  30. Evans, L. D. et al. Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways. Cell Rep. 22, 3612–3624 (2018). · DOI
  31. Calafate, S., Flavin, W., Verstreken, P. & Moechars, D. Loss of bin1 promotes the propagation of tau pathology. Cell Rep. 17, 931–940 (2016). · DOI · Paper page
  32. Falcon, B., Noad, J., McMahon, H., Randow, F. & Goedert, M. Galectin-8-mediated selective autophagy protects against seeded tau aggregation. J. Biol. Chem. 293, 2438–2451 (2018). · DOI
  33. Cooper, J. M. et al. SORL1 is a receptor for tau that promotes tau seeding. J. Biol. Chem. 300, 107313 (2024). · DOI · Paper page
  34. Dujardin, S. et al. Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PloS ONE 9, e100760 (2014). · DOI
  35. Bespalov, A., Courade, J.-P., Khiroug, L., Terstappen, G. C. & Wang, Y. A call for better understanding of target engagement in Tau antibody development. Drug Discov. Today 27, 103338 (2022). · DOI
  36. Mukadam, A. S. et al. Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models. Science 379, 1336–1341 (2023). · DOI
  37. Gaikwad, S. et al. Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice. Sci. Transl. Med. 16, eadj5958 (2024). · DOI
  38. McEwan, W. A. et al. Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc. Natl. Acad. Sci. USA 114, 574–579 (2017). · DOI · Paper page
  39. Rose, K. et al. Tau fibrils induce nanoscale membrane damage and nucleate cytosolic tau at lysosomes. Proc. Natl. Acad. Sci. USA 121, e2315690121 (2024). · DOI
  40. Mirbaha, H. et al. Inert and seed-competent tau monomers suggest structural origins of aggregation. ELife 7, e36584 (2018). · DOI
  41. Despres, C. et al. Major differences between the self-assembly and seeding behavior of heparin-induced and in vitro phosphorylated tau and their modulation by potential inhibitors. ACS Chem. Biol. 14, 1363–1379 (2019). · DOI
  42. Zhang, W. et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer’s and Pick’s diseases. ELife 8, e43584 (2019). · DOI · Paper page
  43. Sibille, N. et al. Structural impact of heparin binding to full-length Tau as studied by NMR spectroscopy. Biochemistry 45, 12560–12572 (2006). · DOI
  44. Peyvandi, F. et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N. Engl. J. Med. 374, 511–522 (2016). · DOI
  45. Oyama, S. et al. A novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis. Sci. Rep. 12, 18102 (2022). · DOI
  46. Wu, X. & Rapoport, T. A. Cryo-EM structure determination of small proteins by nanobody-binding scaffolds (Legobodies). Proc. Natl. Acad. Sci. USA 118, e2115001118 (2021). · DOI
  47. McArthur, N. et al. Development of a pan-tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates. Biotechnol. Prog. 40, e3463 (2024). · DOI
  48. Albert, M. et al. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain J. Neurol. 142, 1736–1750 (2019). · DOI
  49. Courade, J.-P. et al. Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau. Acta Neuropathol. 136, 729–745 (2018). · DOI
  50. Moutel, S. et al. NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. ELife 5, e16228 (2016). · DOI
  51. Moreira, G. G. et al. Dynamic interactions and Ca2+-binding modulate the holdase-type chaperone activity of S100B preventing tau aggregation and seeding. Nat. Commun. 12, 6292 (2021). · DOI · Paper page
  52. Danis, C. et al. Nuclear magnetic resonance spectroscopy for the identification of multiple phosphorylations of intrinsically disordered proteins. J. Vis. Exp. https://doi.org/10.3791/55001 (2016). · DOI
  53. Lee, W., Rahimi, M., Lee, Y. & Chiu, A. POKY: a software suite for multidimensional NMR and 3D structure calculation of biomolecules. Bioinformatics 37, 3041–3042 (2021). · DOI
  54. Hunter, J. D. Matplotlib: A 2D graphics environment. Comput. Sci. Eng. 9, 90–95 (2007). · DOI · Paper page
  55. Karlsson, R., Katsamba, P. S., Nordin, H., Pol, E. & Myszka, D. G. Analyzing a kinetic titration series using affinity biosensors. Anal. Biochem. 349, 136–147 (2006). · DOI · Paper page
  56. Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 66, 22–25 (2010). · DOI
  57. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355–367 (2011). · DOI
  58. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010). · DOI · Paper page

Cited by

See all 21

Metadata

Authors
Danis, C., Dupré, E., Bouillet, T., Denéchaud, M., Lefebvre, C., Nguyen, M., Mortelecque, J., Cantrelle, F.-X., Rain, J.-C., Hanoulle, X., Colin, M., Buée, L., & Landrieu, I.
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2025-04-02
Volume
16
Issue
1
ISSN
2041-1723
DOI
10.1038/s41467-025-58383-4
PMC
PMC11965310
Cited by
21
References
8
Language
en
Licence
Funders
  • Agence Nationale de la Recherche (ANR-11-LABX-01, ANR-18-CE44-0016, ANR-22-CE92-0061)
  • European Commission (GA101119596)
  • Association France Alzheimer (6433)
  • The Rainwater Charitable Foundation & Alzheimer’s Association

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.